New Advances in Follicular Lymphoma: A Focus on the Expanding Role of PI3K Inhibitors

New Advances in Follicular Lymphoma: A Focus on the Expanding Role of PI3K Inhibitors

Wednesday, June 16, 2021
Webinar -- 7:00 PM ET
https://www.clinicaloptions.com/FLPI3K2021Join1

Agenda

  • Overview of current follicular lymphoma (FL) treatment landscape
  • Existing and emerging clinical data of available PI3K Inhibitors used for the treatment of relapsed/refractory (R/R) FL
  • Selecting and sequencing PI3K inhibitors in the R/R setting
  • The evolving role of PI3K inhibitors for patients with FL

Faculty

Faculty
John Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Faculty
Nathan Fowler, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to optimally use PI3K inhibitor therapy in the management of patients with relapsed/refractory follicular lymphoma.

Target Audience
This educational program is intended for medical oncologists, hematologists, and other healthcare providers who treat patients with follicular lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate current evidence and best practice recommendations plus patient-related and disease-related characteristics to select patients who are candidates to receive PI3K inhibitors for the treatment of R/R FL
  • Select appropriate PI3K inhibitor therapy for individual patients during the COVID-19 pandemic based on comorbidities, risk of exposure, adverse event profiles, and mode and frequency of administration
  • Describe key differences among available PI3K inhibitors regarding target, indication, clinical trial safety and efficacy data, and dosing and administration used for the treatment of R/R FL
  • Monitor for and manage adverse events of treatment in patients with R/R FL being treated with PI3K inhibitors to support quality of life and continuation of treatment
  • Apply emerging clinical trial findings on novel therapies when formulating treatment recommendations for PI3K inhibitors for patients with FL in the frontline and R/R settings

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.